FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100089927> ?p ?o ?g. }

• W2100089927 endingPage "59" @default.
• W2100089927 startingPage "53" @default.
• W2100089927 abstract "Objectives. Recent clinical trials have implied the cytotoxic and antiproliferative effects of combining 5-fluorouracil and interferon-alpha in the treatment of metastatic renal cell cancer. We therefore conducted an open multicenter trial to test the efficacy of such a combination on this cancer. Methods. Human lymphoblastoid interferon (3 MIU per patient) was administered subcutaneously three times weekly for 12 weeks, while 5-fluorouracil was administered (600 mg/m2/day) as a continuous infusion for the first 5 days, followed by an intravenous bolus infusion of 600 mg/m2 once a week from the 3rd week until the 12th week. Results. Of the 63 patients entered into the trial, 55 were eligible and evaluable for systemic toxicities, and 53 were evaluable for their response. All patients had undergone a prior nephrectomy, and their European Cooperative Oncology Group (ECOG) performance status ranged from 0 to 3 (median 0). Three complete and eight partial responses were induced, with an overall response rate of 20.0%. The median time to progression and the median survival time were 11 and 33 months, respectively. World Health Organization grade 3 toxicities were observed in 8 patients; however, no grade 4 toxicities or toxicity-related deaths were noted. Conclusions. Combination therapy of interferon-alpha plus 5-fluorouracil at the above-described dosage and schedule produced no better responses than interferon monotherapies. Prolongation of survival could be attributable to the fair performance status of the patients. This regimen has limited value for the treatment of patients with advanced renal cell cancer." @default.
• W2100089927 created "2016-06-24" @default.
• W2100089927 creator A5004687590 @default.
• W2100089927 creator A5004702538 @default.
• W2100089927 creator A5007596741 @default.
• W2100089927 creator A5009251932 @default.
• W2100089927 creator A5029264235 @default.
• W2100089927 creator A5065959705 @default.
• W2100089927 creator A5066132380 @default.
• W2100089927 creator A5069464324 @default.
• W2100089927 creator A5082141862 @default.
• W2100089927 creator A5083988552 @default.
• W2100089927 creator A5087352140 @default.
• W2100089927 date "1999-01-01" @default.
• W2100089927 modified "2023-09-23" @default.
• W2100089927 title "Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial" @default.
• W2100089927 cites W100810723 @default.
• W2100089927 cites W1969753550 @default.
• W2100089927 cites W1979288272 @default.
• W2100089927 cites W1987362066 @default.
• W2100089927 cites W2008634856 @default.
• W2100089927 cites W2023720862 @default.
• W2100089927 cites W2026953317 @default.
• W2100089927 cites W2033597026 @default.
• W2100089927 cites W2037104948 @default.
• W2100089927 cites W2049689068 @default.
• W2100089927 cites W2055223991 @default.
• W2100089927 cites W2063454635 @default.
• W2100089927 cites W2078007924 @default.
• W2100089927 cites W2081705684 @default.
• W2100089927 cites W2097134027 @default.
• W2100089927 cites W2114180295 @default.
• W2100089927 cites W2125622371 @default.
• W2100089927 cites W2140528681 @default.
• W2100089927 cites W2224128977 @default.
• W2100089927 cites W2230952198 @default.
• W2100089927 cites W2328922514 @default.
• W2100089927 cites W2887131627 @default.
• W2100089927 cites W4243279040 @default.
• W2100089927 cites W4248915126 @default.
• W2100089927 cites W4301452248 @default.
• W2100089927 cites W4366065881 @default.
• W2100089927 doi "https://doi.org/10.1016/s0090-4295(98)00459-2" @default.
• W2100089927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9886588" @default.
• W2100089927 hasPublicationYear "1999" @default.
• W2100089927 type Work @default.
• W2100089927 sameAs 2100089927 @default.
• W2100089927 citedByCount "14" @default.
• W2100089927 countsByYear W21000899272012 @default.
• W2100089927 countsByYear W21000899272013 @default.
• W2100089927 countsByYear W21000899272017 @default.
• W2100089927 crossrefType "journal-article" @default.
• W2100089927 hasAuthorship W2100089927A5004687590 @default.
• W2100089927 hasAuthorship W2100089927A5004702538 @default.
• W2100089927 hasAuthorship W2100089927A5007596741 @default.
• W2100089927 hasAuthorship W2100089927A5009251932 @default.
• W2100089927 hasAuthorship W2100089927A5029264235 @default.
• W2100089927 hasAuthorship W2100089927A5065959705 @default.
• W2100089927 hasAuthorship W2100089927A5066132380 @default.
• W2100089927 hasAuthorship W2100089927A5069464324 @default.
• W2100089927 hasAuthorship W2100089927A5082141862 @default.
• W2100089927 hasAuthorship W2100089927A5083988552 @default.
• W2100089927 hasAuthorship W2100089927A5087352140 @default.
• W2100089927 hasConcept C121608353 @default.
• W2100089927 hasConcept C126322002 @default.
• W2100089927 hasConcept C126894567 @default.
• W2100089927 hasConcept C141071460 @default.
• W2100089927 hasConcept C203014093 @default.
• W2100089927 hasConcept C2776178377 @default.
• W2100089927 hasConcept C2776694085 @default.
• W2100089927 hasConcept C2776907518 @default.
• W2100089927 hasConcept C2777472916 @default.
• W2100089927 hasConcept C2777701055 @default.
• W2100089927 hasConcept C2780456651 @default.
• W2100089927 hasConcept C2781228144 @default.
• W2100089927 hasConcept C2781413609 @default.
• W2100089927 hasConcept C2909179924 @default.
• W2100089927 hasConcept C43376680 @default.
• W2100089927 hasConcept C535046627 @default.
• W2100089927 hasConcept C71924100 @default.
• W2100089927 hasConcept C90924648 @default.
• W2100089927 hasConceptScore W2100089927C121608353 @default.
• W2100089927 hasConceptScore W2100089927C126322002 @default.
• W2100089927 hasConceptScore W2100089927C126894567 @default.
• W2100089927 hasConceptScore W2100089927C141071460 @default.
• W2100089927 hasConceptScore W2100089927C203014093 @default.
• W2100089927 hasConceptScore W2100089927C2776178377 @default.
• W2100089927 hasConceptScore W2100089927C2776694085 @default.
• W2100089927 hasConceptScore W2100089927C2776907518 @default.
• W2100089927 hasConceptScore W2100089927C2777472916 @default.
• W2100089927 hasConceptScore W2100089927C2777701055 @default.
• W2100089927 hasConceptScore W2100089927C2780456651 @default.
• W2100089927 hasConceptScore W2100089927C2781228144 @default.
• W2100089927 hasConceptScore W2100089927C2781413609 @default.
• W2100089927 hasConceptScore W2100089927C2909179924 @default.
• W2100089927 hasConceptScore W2100089927C43376680 @default.
• W2100089927 hasConceptScore W2100089927C535046627 @default.
• W2100089927 hasConceptScore W2100089927C71924100 @default.

• next